Mark Christopher Legrand Baylis
Keine laufenden Positionen mehr
Profil
Mark Christopher Legrand Baylis worked as a Director of Quality & Regulatory Affairs at Deltex Medical Group Plc and as a Director at Deltex Medical Ltd.
Ehemalige bekannte Positionen von Mark Christopher Legrand Baylis
Unternehmen | Position | Ende |
---|---|---|
Deltex Medical Ltd.
Deltex Medical Ltd. Medical DistributorsDistribution Services Part of Deltex Medical Group Plc, Deltex Medical Ltd. is a British manufacturer of fluid management devices, including the CardioQ-ODM and CardioQ-ODM+. The company is based in Chichester, UK. The British company provides a single platform, TrueVue™ with ODM+, measuring flow and pressure directly, which includes Oesophageal Doppler Monitoring, Pulse Pressure Waveform Analysis (PPWA) & High Definition Impedance Cardiography (HD-ICG) in a single unit. Enhanced Recovery has evolved, requiring individualised goal directed haemodynamic therapy, optimised through cardiac output monitoring. TrueVue™ Loops plots aortic blood flow velocity and pressure, on every heartbeat, displaying it graphically, providing a complete haemodynamic picture, in real-time. The company was founded in 1992. The CEO is Andrew Jonathan Mears. | Direktor/Vorstandsmitglied | 19.10.2018 |
DELTEX MEDICAL GROUP PLC | General Counsel | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
DELTEX MEDICAL GROUP PLC | Health Technology |
Private Unternehmen | 1 |
---|---|
Deltex Medical Ltd.
Deltex Medical Ltd. Medical DistributorsDistribution Services Part of Deltex Medical Group Plc, Deltex Medical Ltd. is a British manufacturer of fluid management devices, including the CardioQ-ODM and CardioQ-ODM+. The company is based in Chichester, UK. The British company provides a single platform, TrueVue™ with ODM+, measuring flow and pressure directly, which includes Oesophageal Doppler Monitoring, Pulse Pressure Waveform Analysis (PPWA) & High Definition Impedance Cardiography (HD-ICG) in a single unit. Enhanced Recovery has evolved, requiring individualised goal directed haemodynamic therapy, optimised through cardiac output monitoring. TrueVue™ Loops plots aortic blood flow velocity and pressure, on every heartbeat, displaying it graphically, providing a complete haemodynamic picture, in real-time. The company was founded in 1992. The CEO is Andrew Jonathan Mears. | Distribution Services |